Timbuktu Capital Management LLC Buys Shares of 2,439 iShares Biotechnology ETF $IBB

Timbuktu Capital Management LLC purchased a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 2,439 shares of the financial services provider’s stock, valued at approximately $464,000. iShares Biotechnology ETF comprises about 0.7% of Timbuktu Capital Management LLC’s holdings, making the stock its 21st largest holding.

A number of other institutional investors have also recently made changes to their positions in IBB. World Investment Advisors boosted its holdings in shares of iShares Biotechnology ETF by 50.4% in the fourth quarter. World Investment Advisors now owns 11,853 shares of the financial services provider’s stock worth $2,000,000 after acquiring an additional 3,973 shares during the period. BNP Paribas Financial Markets raised its stake in shares of iShares Biotechnology ETF by 11.4% during the 4th quarter. BNP Paribas Financial Markets now owns 2,133,461 shares of the financial services provider’s stock valued at $360,064,000 after purchasing an additional 218,066 shares during the period. HighTower Advisors LLC raised its stake in shares of iShares Biotechnology ETF by 35.5% during the 4th quarter. HighTower Advisors LLC now owns 70,519 shares of the financial services provider’s stock valued at $11,901,000 after purchasing an additional 18,479 shares during the period. Southern Capital Advisors LLC lifted its holdings in iShares Biotechnology ETF by 20.7% during the 1st quarter. Southern Capital Advisors LLC now owns 28,186 shares of the financial services provider’s stock worth $4,759,000 after purchasing an additional 4,833 shares in the last quarter. Finally, Kestra Advisory Services LLC boosted its stake in iShares Biotechnology ETF by 12.2% in the 1st quarter. Kestra Advisory Services LLC now owns 47,461 shares of the financial services provider’s stock worth $8,014,000 after purchasing an additional 5,155 shares during the period. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

Shares of NASDAQ IBB opened at $211.92 on Friday. iShares Biotechnology ETF has a 52 week low of $138.79 and a 52 week high of $217.12. The business has a 50-day simple moving average of $198.05 and a two-hundred day simple moving average of $180.25.

iShares Biotechnology ETF Cuts Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Monday, June 15th were issued a dividend of $0.0238 per share. This represents a $0.10 dividend on an annualized basis and a yield of 0.0%. The ex-dividend date of this dividend was Monday, June 15th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.